Persistent Fetal Circulation Syndrome

Subscribe to Selected New Research on Persistent Fetal Circulation Syndrome

62 relevant articles (1 outcomes, 0 trials/studies) found for this Disease

Description: A syndrome of persistent PULMONARY HYPERTENSION in the newborn infant (INFANT, NEWBORN) without demonstrable HEART DISEASES. This neonatal condition can be caused by severe pulmonary vasoconstriction (reactive type), hypertrophy of pulmonary arterial muscle (hypertrophic type), or abnormally developed pulmonary arterioles (hypoplastic type). The newborn patient exhibits CYANOSIS and ACIDOSIS due to the persistence of fetal circulatory pattern of right-to-left shunting of blood through a patent ductus arteriosus (DUCTUS ARTERIOSUS, PATENT) and at times a patent foramen ovale (FORAMEN OVALE, PATENT).

Also Known As:

Circulation, Persistent Fetal; Persistent Fetal Circulation; Fetal Circulation, Persistent; Hypertension, Pulmonary, of Newborn, Persistent; Persistent Pulmonary Hypertension of Newborn

Relationship Network

Disease Context: Research Results

Respiratory Tract Diseases: 373

Lung Diseases: 8791

Pulmonary Hypertension: 7464

Persistent Fetal Circulation Syndrome: 62

Congenital, Hereditary, and Neonatal Diseases and Abnormalities: 422

Diseases Newborn Infant

Persistent Fetal Circulation Syndrome: 62

Related Diseases

1.	Diaphragmatic Hernia
2.	Meconium Aspiration Syndrome
3.	Respiratory Insufficiency (Respiratory Failure)
4.	Asphyxia (Suffocation)
5.	Syndrome

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Persistent Fetal Circulation Syndrome:

1.	Tolazoline (Priscoline)FDA Link 01/01/1987 - "The effects of two doses of tolazoline have been compared in 2 groups of newborns suffering from the persistent fetal circulation syndrome" 01/01/1979 - "In pediatric cardiology tcPO2 is useful in monitoring cyanotic children given high-risk therapy such as balloon septostomy or drugs with controversial effects such as tolazoline in persistent fetal circulation" 10/01/1978 - "Transcutaneous PO2 monitoring in infants with persistent fetal circulation who are receiving tolazoline therapy." 01/01/1987 - "In a first time, the outcome was favourable after the correction of acidosis and treatment with tolazoline of a persistent fetal circulation" 12/01/1980 - "There were 47 seriously-ill neonates with medical causes of respiratory distress and 10 infants with severe respiratory distress secondary to a congenital diaphragmatic hernia treated with tolazoline according to a strict protocol designed to manage persistent fetal circulation (PFC)" Order ALL the reference details at left...
2.	OxygenIBA 02/01/1981 - "When these changes occur in lungs with immature, thick saccular walls, there is a decreased surface for oxygen exchange and an increased pulmonary vascular resistance resulting in a persistent fetal circulation." 01/01/1984 - "The group 2 and 3 infants suffered clinical and neurological evidence of hypoxic-ischemic brain injury from perinatal asphyxia; however, the infants in group 2 suffered additional problems such as meconium aspiration, persistent fetal circulation with ongoing hypoxemia as measured by transcutaneous or umbilical arterial oxygen monitoring" 01/01/2004 - "Risk factors of mortality by univariate analysis were: outborn babies, resuscitation before admission, first born baby, low pH, high oxygen index (OI), high alveolar-arterial oxygen tension gradient (AaDO2) at admission, high OI and AaDO2 at 2 hours after admission, shock, pneumothorax, asphyxia, pulmonary hemorrhage, persistent pulmonary hypertension of newborn (PPHN), and renal failure" 03/01/2008 - "RATIONALE: Inhaled nitric oxide (iNO), used for treatment of persistent pulmonary hypertension of newborn (PPHN), is an oxygen free radical with potential for lung injury" 05/01/1983 - "Three critically ill infants who had persistent fetal circulation postoperatively, refractile to tolazoline and 100% oxygen with mechanical ventilation including continuous positive airway pressure, responded favourably to prolonged manual hyperventilation" Order ALL the reference details at left...
3.	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/01/2003 - "Persistent pulmonary hypertension of newborn (PPHN) is associated with decreased nitric oxide (NO) release and impaired pulmonary vasodilation" 04/01/2001 - "Baby A presented persistent pulmonary hypertension of newborn, and received nitric oxide inhalation" 11/01/1999 - "Nitric oxide (NO), and extracorporeal membrane oxygenation (ECMO) were instituted as supportive care because of profound persistent fetal circulation (PFC)" 02/01/2007 - "CONCLUSION: Inhaled nitric oxide should be used early in severe hypoxic respiratory failure with persistent pulmonary hypertension of newborn and can improve survival rates without any major immediate side effects." 03/01/2008 - "RATIONALE: Inhaled nitric oxide (iNO), used for treatment of persistent pulmonary hypertension of newborn (PPHN), is an oxygen free radical with potential for lung injury" Order ALL the reference details at left...
4.	Dopamine (Intropin)FDA LinkGeneric 01/01/2001 - "Although epinephrine preserves the SAP/PAP ratio, dopamine shows preferential pulmonary vasoconstriction, which might be detrimental if it also occurs during the management of infants with persistent fetal circulation" 08/05/1984 - "Tolazoline and dopamine in the management of persistent fetal circulation]" 10/01/1983 - "The combined application of Tolazoline and Dopamine for the treatment of the persistent fetal circulation syndrome showed that Dopamine prevented the most common side effects of Tolazoline i.e" 10/01/1983 - "Tolazoline and dopamine in the treatment of the persistent fetal circulation syndrome]" 01/01/1997 - "Plasma lactate levels were significantly elevated with epinephrine infusion 3.2 microg/kg/min. The differential responses of dopamine and epinephrine on pulmonary and mesenteric circulations may be significant in the pathophysiology and management of persistent fetal circulation and necrotizing enterocolitis." Order ALL the reference details at left...
5.	Alprostadil (Muse)FDA LinkGeneric 11/01/1993 - "Lipo-PGE1 may promote ductus arteriosus dilatation in cases of persistent fetal circulation." 01/01/2004 - "PGE1 treatment was indicated by ductus dependent systemic circulation in 16 cases, ductus dependent pulmonary circulation in 17 cases, transposition of the great arteries in 13 cases and pulmonary hypertension (persistent fetal circulation) in three cases" 11/01/1993 - "We report a case of congenital diaphragmatic hernia in which aneurysmal dilatation of ductus arteriosus developed after lipo-prostaglandin E1 (PGE1) therapy for persistent fetal circulation" 04/01/1986 - "Ductal flow changes could be documented after prostaglandin E1 therapy in patients with ductus-dependent heart disease or after tolazoline therapy in patients with persistent fetal circulation" 04/01/1981 - "This encouraging experience indicates that the pattern of persistent fetal circulation in the newborn infant who has undergone repair of a diaphragmatic hernia can be successfully managed with ECMO even when efforts to lower pulmonary hypertension and improve oxygenation with vasodilators (tolazoline, phenothiazine, acetylcholine, or prostaglandin E1) and have been ineffective" Order ALL the reference details at left...
6.	Epoprostenol (Prostacyclin)FDA Link 01/01/1992 - "Prostacyclin in the treatment of persistent fetal circulation syndrome]" 09/22/1979 - "Use of prostacyclin in persistent fetal circulation." 06/23/1979 - "Use of prostacyclin in persistent fetal circulation." Order ALL the reference details at left...
7.	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 11/01/1998 - "Prolongation of gestation and labour, constriction of the ductus arteriosus, persistent fetal circulation, impairment of renal function and bleeding are risks of third trimester exposure of pregnant women to all inhibitors of cyclo-oxygenase" 04/01/1983 - "Administration of indomethacin, a typical representative agent among the prostaglandin synthetase inhibitors (PGSI) causes contraction of the fetal ductus arteriosus and recently the relationship between these PGSI-type agents and the development of persistent fetal circulation (PFC) has been gaining attention in medical circles" Order ALL the reference details at left...
8.	Indomethacin (Indometacin)FDA LinkGeneric 02/01/1981 - "Effects of indomethacin on fetal rat lungs: a possible cause of persistent fetal circulation (PFC)." 04/01/1983 - "Administration of indomethacin, a typical representative agent among the prostaglandin synthetase inhibitors (PGSI) causes contraction of the fetal ductus arteriosus and recently the relationship between these PGSI-type agents and the development of persistent fetal circulation (PFC) has been gaining attention in medical circles" Order ALL the reference details at left...
9.	Epinephrine (Adrenaline)FDA LinkGeneric 01/01/2001 - "Although epinephrine preserves the SAP/PAP ratio, dopamine shows preferential pulmonary vasoconstriction, which might be detrimental if it also occurs during the management of infants with persistent fetal circulation" 01/01/1997 - "Plasma lactate levels were significantly elevated with epinephrine infusion 3.2 microg/kg/min. The differential responses of dopamine and epinephrine on pulmonary and mesenteric circulations may be significant in the pathophysiology and management of persistent fetal circulation and necrotizing enterocolitis." Order ALL the reference details at left...
10.	tranilast (N 5')IBA 03/01/1980 - "Pulmonary artery pressure responses caused by MPA balloon inflation were measured in ten human newborn infants with cardiac failure (n = 5) or persistent fetal circulation (n = 5)" 03/01/2001 - "The underlying clinical conditions include meconium aspiration syndrome (n = 8), perinatal asphyxia (n = 7), respiratory distress syndrome (n = 5), sepsis and/or pneumonia (n = 4), congenital diaphragmatic hernia (n = 3) and idiopathic persistent fetal circulation (n = 2)" Order ALL the reference details at left...

Therapies and Procedures

1.	Extracorporeal Membrane Oxygenation (ECMO) 02/01/2003 - "This newest ECMO apparatus was clinically used in 3 neonates with severe lung hypoplasia and persistent fetal circulation" 02/01/1991 - "In particular, all five patients whose pathological condition needing ECMO was persistent fetal circulation (PFC), survived" 12/03/1988 - "Persistent fetal circulation and extracorporeal membrane oxygenation." 10/01/1982 - "A retrospective analysis of 93 consecutive children with congenital posterolateral diaphragmatic hernia (CDH) was performed to determine outcome, ability to predict the development of persistent fetal circulation (PFC) requiring pharmacologic or extracorporeal membrane oxygenation (ECMO), and whether drugs or ECMO have improved survival" 08/01/1996 - "Six newborns (age range, 0 to 5 days; weight, 2.4 to 3.1 kg) were treated with venoarterial ECMO, with additional placement of a cephalic venous catheter, for meconium aspiration (4) or persistent fetal circulation (2)" Order ALL the reference details at left...
2.	Neonatal Intensive Care 08/01/1982 - "Sixty neonates who were transferred to a neonatal intensive care unit during a four-year period had diagnoses of persistent fetal circulation (PFC)" 09/01/1986 - "Other frequent clinical complications included abnormal CNS findings during the neonatal intensive care unit stay (ten infants), acidosis (pH less than 7.25) on the initial blood gas test (eight infants), and persistent fetal circulation in all seven infants with birth weights greater than 1,500 g" Order ALL the reference details at left...
3.	High-Frequency Ventilation 01/01/1994 - "High frequency ventilation (HVF) was used in 17 newborns with severe respiratory distress due to persistent fetal circulation" 04/01/1989 - "High-frequency oscillation for persistent fetal circulation after repair of congenital diaphragmatic hernia." Order ALL the reference details at left...
4.	Continuous Positive Airway Pressure 05/01/1983 - "Three critically ill infants who had persistent fetal circulation postoperatively, refractile to tolazoline and 100% oxygen with mechanical ventilation including continuous positive airway pressure, responded favourably to prolonged manual hyperventilation" Order ALL the reference details at left...
5.	Resuscitation 01/01/2004 - "Risk factors of mortality by univariate analysis were: outborn babies, resuscitation before admission, first born baby, low pH, high oxygen index (OI), high alveolar-arterial oxygen tension gradient (AaDO2) at admission, high OI and AaDO2 at 2 hours after admission, shock, pneumothorax, asphyxia, pulmonary hemorrhage, persistent pulmonary hypertension of newborn (PPHN), and renal failure" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Persistent Fetal Circulation Syndrome

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>